LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair. Proper stacking requires understanding each compound's mechanism and timing.
What Is LL-37 Stacking?
Stacking means combining LL-37 with one or more complementary peptides to potentially achieve synergistic effects. Because different peptides work through different mechanisms, strategic combinations can target multiple pathways simultaneously.
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What Is the Best LL-37 Stack?
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
This combination is popular because it targets multiple mechanisms without significant overlap in side-effect profiles.
How Does LL-37 Stack With BPC-157?
BPC-157 (Body Protection Compound-157) is a Pentadecapeptide (15 amino acids) that works through BPC-157 upregulates growth hormone receptors and promotes angiogenesis (new blood vessel formation) through the FAK-paxillin pathway, which is critica.
Combined with LL-37's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement, this stack covers tissue repair, gut healing, tendon and ligament recovery, wound healing, neuroprotection as well.
Typical stacking protocol: LL-37 at 100-500 mcg (topical/local application) topical or local application as needed alongside BPC-157 at 200-500 mcg once or twice daily. See our BPC-157 guide for details.
How Does LL-37 Stack With AOD-9604?
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog that works through Activates beta-3 adrenergic receptors in adipose tissue, triggering cAMP-mediated lipolysis and release of stored fat for energy. Suppresses lipogenes.
Combined with LL-37's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement, this stack covers fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation as well.
Typical stacking protocol: LL-37 at 100-500 mcg (topical/local application) topical or local application as needed alongside AOD-9604 at 250-1000 mcg daily once daily, ideally morning fasted. See our AOD-9604 guide for details.
How Does LL-37 Stack With Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a Synaptogenic neuropeptide, HGF/c-Met pathway agonist that works through Potentiates hepatocyte growth factor (HGF) and its receptor c-Met, driving synaptogenesis (new synapse formation). Preclinical data shows it is millio.
Combined with LL-37's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement, this stack covers enhanced synaptogenesis, improved cognitive function, memory enhancement, neuroprotection, increased dendritic spine density as well.
Typical stacking protocol: LL-37 at 100-500 mcg (topical/local application) topical or local application as needed alongside Dihexa at 10-40 mg daily once daily. See our Dihexa guide for details.
How Do You Time a LL-37 Stack?
When stacking, timing each injection based on half-life is important. LL-37 has a half-life of rapidly degraded by proteases; major clinical limitation, which influences when to administer relative to other compounds.
Some researchers inject all peptides at the same time; others stagger by 15-30 minutes. There's limited data on whether timing within the same session matters significantly.
What Should You NOT Stack With LL-37?
Avoid stacking peptides with similar mechanisms of action at full doses — this can lead to receptor desensitization without proportional benefit. Also avoid combining compounds where side-effect profiles overlap significantly.
When in doubt, introduce one new compound at a time to isolate its effects before building a full stack.
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Bottom Line on LL-37 Stacking
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair. Start with a single compound, assess response, then add complements.
See our stacking and cycling guide for general principles.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Cycle Guide
- LL-37 Research
- BPC-157 Complete Guide
Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.